Cargando…

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma

Background: The advent of immune checkpoint inhibitors (ICIs) has altered the outlook for cancer treatment. The estimation of predictive biomarkers could contribute to maximizing the benefits from ICIs treatment. Here, we explored the association between HYDIN mutations (HYDIN-MUT) in melanoma and I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Liu, Tianrui, Kuang, Chunlei, Li, Zhendong, Qiu, Xiaoyan, Chen, Wenhong, Deng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496993/ https://www.ncbi.nlm.nih.gov/pubmed/37595251 http://dx.doi.org/10.18632/aging.204925

Ejemplares similares

Mutations in Hydin impair ciliary motility in mice
por: Lechtreck, Karl-Ferdinand, et al.
Publicado: (2008)

Hydin flips flagella
por: LeBrasseur, Nicole
Publicado: (2007)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Effects of hormones on intestinal stem cells
por: Liu, Li, et al.
Publicado: (2023)

Hydin seek: finding a function in ciliary motility
por: Smith, Elizabeth F.
Publicado: (2007)

1q21.1 microduplication: large verbal–nonverbal performance discrepancy and ddPCR assays of HYDIN/HYDIN2 copy number
por: Xavier, Jean, et al.
Publicado: (2018)

Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
por: Zhang, Lilong, et al.
Publicado: (2023)

Novel HYDIN variants associated with male infertility in two Chinese families
por: Yu, Hui, et al.
Publicado: (2023)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors
por: Zhang, Lilong, et al.
Publicado: (2022)

Chlamydomonas reinhardtii hydin is a central pair protein required for flagellar motility
por: Lechtreck, Karl-Ferdinand, et al.
Publicado: (2007)

The hydrocephalus inducing gene product, Hydin, positions axonemal central pair microtubules
por: Dawe, Helen R, et al.
Publicado: (2007)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Key Molecules of Fatty Acid Metabolism in Gastric Cancer
por: Li, Chunlei, et al.
Publicado: (2022)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy
por: Zhang, Lilong, et al.
Publicado: (2023)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Precise genetic mapping and integrative bioinformatics in Diversity Outbred mice reveals Hydin as a novel pain gene
por: Recla, Jill M., et al.
Publicado: (2014)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma
por: Ying, Haoxuan, et al.
Publicado: (2021)

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
por: Ning, Biao, et al.
Publicado: (2022)

Chimeric analysis with newly established EGFP/DsRed2-tagged ES cells identify HYDIN as essential for spermiogenesis in mice
por: Oura, Seiya, et al.
Publicado: (2018)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
por: Li, Ping, et al.
Publicado: (2018)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma
por: Zhao, Liqin, et al.
Publicado: (2022)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

The Prognostic Significance and Potential Mechanism of Prolyl 3-Hydroxylase 1 in Hepatocellular Carcinoma
por: Li, Chunlei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kukuop2j49efl88rlchgfnl2s7